#ACC21: Novartis whiffs on Entresto study after heart attacks — but that doesn't mean it's going down quietly
If Novartis learned one thing from its interaction with the FDA over its latest heart failure approval for Entresto, it was that missing a primary endpoint may not be the nail in the coffin. Now, Entresto has missed again on a late-stage study in high-risk heart patients, and it’s already sowing the seeds for a path forward regardless.
Novartis’ Entresto couldn’t best standard-of-care ACE inhibitor ramipril in staving off a composite of deaths and heart failure events in patients with left ventricular systolic dysfunction and/or pulmonary congestion who have had a prior heart attack, according to topline data from the Phase III PARADISE-MI study revealed Saturday at the virtual American College of Cardiology meeting.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 109,500+ biopharma pros reading Endpoints daily — and it's free.